Click here to read more Quest articles. print | Print this page
From the Summer/Fall 2016 Quest

Investigators looked for predictors of time to metastasis in men who had non-metastatic prostate cancer at diagnosis, were treated with androgen deprivation therapy (ADT), and then developed castration-resistant prostate cancer (CRPC).

The analysis included 458 men with non-metastatic CRPC. A total of 256 (56%) of men were diagnosed with metastatic prostate cancer over a median follow-up of 36 months. Gleason score 8-10, receiving primary localized treatment, higher PSA levels at CRPC diagnosis and PSA doubling time in 6 months or less were all independently associated with a shorter time to the spread of cancer. The authors wrote, "[These] variables can be used to stratify patients according to metastasis risk."

This study did not find that year of CRPC or age and time from ADT to CRPC were associated with metastatic disease.

The study was published online ahead of print in The Journal of Urology on June 15, 2016.

Close this window